Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi’s Dupixent Is Bucking Lockdown Trend, For Now

Physicians Adopting Telemedicine At Speed

Executive Summary

Its emerging flagship drug maintained rapid growth in Q1, but a longer lockdown will hit all competitors’ new prescriptions.

You may also be interested in...



GSK Plus Sanofi: The COVID-19 Vaccine Dream Team?

While not promising the fastest development time that the world craves, the combined experience and scale of the two vaccine giants bodes well.

Abingworth Adds Stakes To Gilead’s Trodelvy Gamble

The venture capital firm is putting $210m into NSCLC trials for the antibody drug conjugate – with an opportunity in patients who fail on first line immunotherapy the most likely target.

As Vyvgart Surges To Blockbuster Status, Argenx Maps Out Expansion Plans

The European biotech is just getting started with its expansion plans for the drug in generalized myasthenia gravis, while multiple readouts in new autoimmune diseases are expected in 2024.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC142106

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel